|[July 30, 2014]
Research and Markets: Epidermolysis Bullosa - Pipeline Review, H1 2014
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/br5skr/epidermolysis)
has announced the addition of the "Epidermolysis
Bullosa - Pipeline Review, H1 2014" report to their offering.
This report provides comprehensive information on the therapeutic
development for Epidermolysis Bullosa, complete with comparative
analysis at various stages, therapeutics assessment by drug target,
mechanism of action (MoA), route of administration (RoA) and molecule
type, along with latest updates, and featured news and press releases.
It also reviews key players involved in the therapeutic development for
Epidermolysis Bullosa and special features on late-stage and
Drug profiles/records featured in the report undergoes periodic updatin
following a stringent set of processes that ensures that all the
profiles are updated with the latest set of information. Additionally,
processes including live news & deals tracking, browser based alert-box
and clinical trials registries tracking ensure that the most recent
developments are captured on a real time basis.
Reasons to buy
Provides strategically significant competitor information, analysis,
and insights to formulate effective R&D development strategies
Identify emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive advantage
Develop strategic initiatives by understanding the focus areas of
Identify and understand important and diverse types of therapeutics
under development for Epidermolysis Bullosa
Plan mergers and acquisitions effectively by identifying key players
of the most promising pipeline
Devise corrective measures for pipeline projects by understanding
Epidermolysis Bullosa pipeline depth and focus of Indication
Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects
and understanding the factors that drove them from pipeline
RegeneRx Biopharmaceuticals, Inc.
Fibrocell Science, Inc.
For more information visit http://www.researchandmarkets.com/research/br5skr/epidermolysis
[ Back To TMCnet.com's Homepage ]